Merck-Moderna mRNA Cancer Vaccine Cuts Melanoma Risk 42%

A personalized mRNA cancer vaccine jointly developed by Merck and Moderna lowered the risk of recurrence or death by 42% compared with immunotherapy alone in a phase 3 trial, according to Becker's Hospital Review. The vaccine, intismeran autogene, was tested alongside Merck's immunotherapy Keytruda in patients with surgically resected stage 2B to 4 melanoma, a population at high risk of their cancer returning.

The approach is personalized: the vaccine is custom-built to target the specific genetic mutations in each patient's tumor, training the immune system to recognize and attack cancer cells. Pairing that with Keytruda, which releases the brakes on the immune response, appears to produce a stronger combined effect than immunotherapy by itself.

The result adds to mounting evidence that mRNA technology, widely known from COVID-19 vaccines, can be turned against cancer. For hospitals and oncology programs, a positive phase 3 readout moves individualized cancer vaccines closer to the clinic, though regulatory review and the logistics of manufacturing bespoke therapies remain hurdles.